Dr. Hansjoerg Keller

Sr. Investigator I, Novartis Institutes for BioMedical Research, Switzerland

3D Bioprinting of functional human skeletal muscle tissue for drug development

Bio :

Hansjoerg Keller is a Senior Investigator of the Musculoskeletal Disease Area at the Novartis Institutes for BioMedical Research in Basel, Switzerland.

He studied Biochemistry and graduated in Neurochemistry at the Swiss Federal Institute of Technology Z├╝rich (ETHZ), Switzerland in 1988. During his postdoctoral fellowship at the Scripps Research Institute, La Jolla, CA, USA (Prof. J. Gottesfeld) and later at the University of Lausanne (Prof. W. Wahli), he focused on regulation of gene transcription and the role of PPAR nuclear receptors. In 1996, he joined Novartis leading different drug discovery projects including selective estrogen receptor modulators (SERMs) and sclerostin inhibitors for osteoporosis treatment and selective androgen receptor modulators (SARMs) against muscle wasting.

Currently, his research is focused on the identification of novel drug targets for the development of new muscle wasting disease therapies. To this end, he is using 3D bioprinting for the engineering of functional human skeletal muscle tissue models that can be used for the in vitro screening of compounds affecting muscle function such as force and endurance.